{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T18:54:18Z","timestamp":1761418458993},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,3,27]],"date-time":"2007-03-27T00:00:00Z","timestamp":1174953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2007,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background: <\/jats:bold> Chemotherapy\u2010induced nausea and vomiting (CINV) is an important cause of distress for cancer patients. We have evaluated the effectiveness and safety of a new antiemetic aprepitant in improving management of CINV refractory to standard antiemetic therapy in the general oncology setting.<\/jats:p><jats:p><jats:bold>Methods: <\/jats:bold> Retrospective chart review of all patients who received aprepitant from 1 January 2004 to 31 May 2005.<\/jats:p><jats:p><jats:bold>Results: <\/jats:bold> Twenty\u2010six patients received oral aprepitant in addition to 5\u2010hydroxytryptamine blocker and corticosteroid. Eighty\u2010five per cent of the patients were women. Median age was 49\u2003years. More than half patients had early\u2010stage cancers. Majority received anthracycline\u2010based chemotherapy for breast cancer. Fourteen (54%) patients received aprepitant during cycle 2, seven patients (27%) started aprepitant during cycle 4 and one (4%) during cycle 5. Side\u2010effects observed included constipation (27%), fatigue (27%) and diarrhoea (8%). Six (23%) patients did not complete chemotherapy. Two of these had persistent nausea and vomiting, and four experienced diarrhoea, febrile neutropenia and other chemotherapy\u2010related events. Three patients (12%) were hospitalized prior to starting aprepitant because of CINV, and one patient was hospitalized because of CINV while receiving aprepitant. Only six (23%) patients would have been eligible for aprepitant under the reimbursement scheme available at the time.<\/jats:p><jats:p><jats:bold>Conclusion: <\/jats:bold> The addition of aprepitant was associated with improved control of nausea and vomiting and reduction in hospitalization in patients receiving chemotherapy.<\/jats:p>","DOI":"10.1111\/j.1445-5994.2007.01311.x","type":"journal-article","created":{"date-parts":[[2007,3,27]],"date-time":"2007-03-27T11:23:26Z","timestamp":1174994606000},"page":"247-250","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of aprepitant in management of chemotherapy\u2010induced nausea and vomiting"],"prefix":"10.1111","volume":"37","author":[{"given":"J. A. A.","family":"Osorio\u2010Sanchez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Karapetis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Koczwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,3,27]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010548"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.507"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00365579"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(00)00249-9"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198110153051609"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2971"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0936-6555(05)80953-7"},{"issue":"53","key":"e_1_2_5_9_2","first-page":"78","article-title":"Management of cisplatin\u2010induced delayed emesis","volume":"1","author":"Hesketh P","year":"1996","journal-title":"Oncology"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.1.108"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000227646"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.6.1759"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.095"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901213400304"},{"key":"e_1_2_5_15_2","article-title":"Assessing the cost\u2010effectiveness of adding aprepitant to the ASCO standard for prophylaxis of chemotherapy induced nausea and vomiting [abstract no 6009]","author":"Moore SG","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_5_16_2","unstructured":"Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events Version 3.0 DCTD NCI NIH DHHS Mar 31 2003(http:\/\/ctep.cancer.gov) Publish Date: June 10 2003."},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.116"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890901)64:5<1117::AID-CNCR2820640525>3.0.CO;2-R"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.050"},{"key":"e_1_2_5_20_2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1200\/JCO.1996.14.2.644","article-title":"Analysis of cumulative probabilities show that the efficacy of 5HT3 antagonist prophylaxis is not maintained","volume":"14","author":"De Wit R","year":"1996","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.244"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.7.2091"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1445-5994.2007.01311.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1445-5994.2007.01311.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T20:28:07Z","timestamp":1697401687000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1445-5994.2007.01311.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,27]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["10.1111\/j.1445-5994.2007.01311.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1445-5994.2007.01311.x","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,27]]},"assertion":[{"value":"2007-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}